Key Highlights

  • 3.69 is the USD million of Revenue NEXGEL, Inc. (NASDAQ:NXGL) reported for the second quarter of 2026, as the company integrated the BioNX Surgical Business acquired from Celularity, Inc. in April.
  • 2.87 is the USD million net loss reported for the second quarter of 2026, which included USD 756,554 of BioNX intangible amortization and USD 273,710 of one-time transaction-related expenses.
  • 795,000 is the approximate USD Backlog of the BioNX Surgical division at the end of the second quarter, while management said integration and rollout moved at a slower pace than originally anticipated.
  • 20 is the number of pre-split shares combined into one under the Reverse Stock Split that became effective on October 12, 2026, after a proxy vote on share authorization proposals fell short in the summer.

What Investors Expect From NEXGEL, Inc. (NASDAQ:NXGL) on November 16, 2026

The company is scheduled to report third quarter 2026 results on November 16, 2026. The quarter is the first full period to include the BioNX Surgical division, created when the company completed its transaction with Celularity, Inc. in mid-April 2026 with Sequence Life Science, Inc. as strategic partner. The comparison base is the second quarter, when revenue was USD 3.69 million. The prior-year third quarter report was issued on November 11, 2025. The company has not issued formal numeric guidance, and per-share comparisons will reflect the 1-for-20 reverse split effective October 12, 2026.

The Rationale: Last Reported Quarter and Management Outlook for NEXGEL, Inc. (NASDAQ:NXGL)

The second quarter net loss of USD 2.87 million included USD 756,554 of intangible amortization, USD 273,710 of Transaction Costs and USD 144,495 tied to recalling all SilverSeal inventory from Amazon. Management said rollout moved more slowly than planned. Sequence deployed tissue processing specialists to the Celularity New Jersey Facility on August 4, 2026 as part of a plan to move Manufacturing to San Antonio, Texas. SilverSeal began its hospital launch in August, where reimbursement A-codes exist and margins may be higher. Those three items total USD 1,174,759 (calculated), about 41% of the net loss, which implies a loss of about USD 1.70 million without them (calculated).

Valuation, Liquidity and Risks for NEXGEL, Inc. (NASDAQ:NXGL)

Restricted cash of about USD 710,000 tied to the earlier ATW Partners transaction was released and returned to the company after the quarter. Sequence led a USD 5.5 million financing on April 21, 2026 to complete the Acquisition of the Celularity degenerative disease segment, and appointed two directors to the board in May 2026. A Leadership transition and strategic review was announced on August 20, 2026. Risks include Supply chain constraints, the manufacturing transfer, the SilverSeal recall, dependence on one strategic partner, and dilution from further share authorization.

Where Things Stand

NEXGEL, Inc. (NASDAQ:NXGL) reports during a transition year. Revenue of USD 3.69 million and a net loss of USD 2.87 million in the second quarter reflected USD 756,554 of amortization, USD 273,710 of deal costs and a USD 144,495 SilverSeal recall charge. The BioNX Surgical backlog of about USD 795,000, the move of manufacturing to San Antonio and the hospital channel launch for SilverSeal are the operating variables. Sequence's USD 5.5 million financing and the released USD 710,000 of restricted cash support liquidity. The net loss equaled about 78% of revenue (calculated). Investors will watch integration pace, gross margin, supply availability and the reverse split effects.